These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 8119326

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC, Lambert JD.
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [Abstract] [Full Text] [Related]

  • 25. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.
    Tuomainen P, Törnwall M, Männistö PT.
    Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199
    [Abstract] [Full Text] [Related]

  • 26. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
    Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A.
    Eur J Pharmacol; 1994 May 12; 257(1-2):53-8. PubMed ID: 8082707
    [Abstract] [Full Text] [Related]

  • 27. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
    Qi Q, Cao L, Li F, Wang H, Liu H, Hao H, Hao K.
    Xenobiotica; 2015 May 12; 45(9):820-7. PubMed ID: 25869243
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E, Lindén IB, Schultz E, Pohto P.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep 12; 346(3):262-6. PubMed ID: 1407012
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
    Jorga KM, Nicholl DJ.
    Br J Clin Pharmacol; 1999 Sep 12; 48(3):449-52. PubMed ID: 10510160
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.
    Heeringa MJ, d'Agostini F, DeBoer P, DaPrada M, Damsma G.
    J Neural Transm (Vienna); 1997 Sep 12; 104(6-7):593-603. PubMed ID: 9444560
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV, Cooper JM, Schapira AH.
    Neuropharmacology; 2004 Mar 12; 46(4):562-9. PubMed ID: 14975680
    [Abstract] [Full Text] [Related]

  • 39. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure.
    Waldmeier PC, Baumann PA, Feldtrauer JJ, Hauser K, Bittiger H, Bischoff S, von Sprecher G.
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep 12; 342(3):305-11. PubMed ID: 1980718
    [Abstract] [Full Text] [Related]

  • 40. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ.
    Neurology; 1994 Jul 12; 44(7):1292-7. PubMed ID: 8035933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.